When it comes to Xiongan New Area, many people will think of the "city of the future" and the highland of innovation. In early September this year.Xionganjian Stem Cell Therapy Platform Officially Unveiled--The Xiongan Center of National Stem Cell Engineering and Technology Research Center was launched to provide full-chain public technical support for cell therapy. During the same period, Beidaihe successfully held the National Symposium on Clinical Research of Cell Therapy, which focused on the in-depth exchanges on stem cell policy, clinical standardization and industrialization application. One north and one south, the two events together promote cell therapy from laboratory to clinical and industrialization faster.

I. Beidaihe Symposium: Focusing on "standardization" and "quality" of cell therapy

The 3rd Cell Therapy Clinical Research Symposium was held in Beidaihe from September 5 to 7, bringing together authoritative experts from PLA General Hospital and Tianjin Cancer Hospital to discuss the breakthroughs of stem cell and somatic cell therapies in the fields of heart disease, neurodegenerative diseases and type 1 diabetes. The meeting focused on: stem cell policy, clinical trial design, ethical regulation and innovation balance, to promote cell therapy research more scientific, standardized and efficient.

Core topics include:

• How to design and implement high quality clinical trials that meet international standards;
• Breakthroughs in stem cell and somatic cell therapy in the areas of heart disease, neurodegenerative diseases, and type 1 diabetes;
• The balance between cellular drug review policy, ethical regulation and innovation.

The conference has set up special sessions, focusing on the promotion of iPSC-derived islet transplantation for diabetes, stem cell intervention in heart failure, CAR-T, NK cell therapy and individualized tumor vaccines and other cutting-edge directions. Roundtable discussions will hit the pain points of the industry: how to avoid homogeneous competition, how to strengthen international cooperation, and how to promote innovation under the premise of safety.

One sentence summary:The key word of the Beidaihe Symposium is "standardization" - a commitment to make cell-based clinical research more scientific, more rigorous, and more translationally valuable.

Xiongan Center inaugurated: creating a "public platform" for cell therapy industrialization

On September 13, the Xiongan Center of the National Stem Cell Engineering and Technology Research Center was officially launched. The center is different from traditional laboratories, but a national cell and gene therapy (CGT) public technology platform based in Xiongan and serving the whole country.

Its main functions include:

• Covering a number of cutting-edge directions such as stem cells, immune cells, exosomes and gene therapy;
• Provide full chain support from early R&D, safety evaluation to pilot conversion and quality control;
• Provide commissioned R&D and testing services for hospitals, research institutes and enterprises.

This means that many cellular technologies in the laboratory stage can achieve process validation and standardized production in the Xiongan Center in the future, accelerating their clinical application and industrialization landing. For Xiongan New Area, the center is not only the core infrastructure for the life and health industry, but also an important window to demonstrate its institutional innovation and technology gathering capabilities.

Third, why are these two things worth looking at together?

Beidaihe Conference answers the question of "how to do standardized research", while Xiongan Center provides "how to realize translational support". Together, they constitute a key node in the ecological closed loop of "research-clinical-industry" in the field of cell therapy in China.

This also highlights the special position of Hebei Province in the strategic layout of national life sciences: not only can Beidaihe host high-end academic conferences and gather consensus to formulate norms, but also take advantage of the innovation mechanism and platform policy of Xiongan New Area to promote the landing of results and industrial agglomeration.

Conclusion: From "Single Point Breakthrough" to "Ecological Construction"

Beidaihe and Xiong'an, one after the other within a week, released a clear signal: China's cell therapy is stepping into a new stage of standardization and platform development.

For patients, more safe and effective therapeutic options are worth looking forward to; for the industry, an accelerated channel from laboratory to clinic is opening. When the standardization and platform are improving, the next key lies in who can take the lead in producing internationally convincing clinical evidence, which will really make cell therapy from "researchable" to "usable".

Information source: Qinhuangdao News, Hebei News, China Pharmaceutical Biotechnology Association

Disclaimer: This article is intended only to disseminate scientific knowledge and share industry perspectives, and does not constitute any clinical diagnostic advice! The information published by Hangi Stem Cells is not a substitute for the professional advice of a physician or pharmacist. If you have any questions about copyright or other issues, please feel free to contact me.

郑重声明：本文版权归原作者所有，转载文章仅为传播更多信息之目的，如作者信息标记有错误，请第一时间联系我们修改或删除，多谢。